Literature DB >> 874095

Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.

W E Rutherford, P Bordier, P Marie, K Hruska, H Harter, A Greenwalt, J Blondin, J Haddad, N Bricker, E Slatopolsky.   

Abstract

Previous studies from this laboratory demonstrated that secondary hyperparathyroidism in dogs with chronic renal disease may occur, at least in part, as a consequence of the need for progressive adaptation in renal phosphorus (P) excretion that occurs as glomerular filtration rate falls. However, the studies were of relatively short duration. Moreover, no information emerged regarding a potential role of calcium malabsorption in the pathogenesis of secondary hyperparathyroidism. The short duration of the protocol did not lend itself to the study of the effect of P control or the administration of vitamin D in the pathogenesis of renal osteodystrophy. In the present studies, 14 dogs with experimental chronic renal disease were studied serially for a period of 2 yr. Each animal was studied first with two normal kidneys on an intake of P of 1,200 mg/day. Then, renal insufficiency was produced by 5/6 nephrectomy. The dogs then were divided into three groups. In group I, 1,200 mg/day P intake was administered for the full 2 yr. In group II, P intake was reduced from the initial 1,200 mg/day, in proportion to the measured fall in glomerular filtration rate, in an effort to obviate the renal adaptation in P excretion. In group III, "proportional reduction" of P intake also was employed; but in addition, 20 mug of 25(OH)D(3) were administered orally three times a week. In group I, parathyroid hormone (PTH) levels rose throughout the 2-yr period reaching a final concentration of 557+/-70 U (normal 10-60). In group II, values for PTH remained normal throughout the 1st yr, increased modestly between the 12th and the 18th mo, but then did not rise after the 18th mo. In group III, no elevation of PTH levels was observed at any time; however, these animals were hypercalcemic. Histomorphologic analyses of the ribs of these dogs were performed serially throughout the 2-yr period. A linear relationship was obtained between the osteoclastic resorption surface and the concentration of circulating immunoreactive PTH. The osteoid volume was greater in group I animals when compared to those in group II. None of the morphologic abnormalities associated with renal osteodystrophy were observed in the animals in the third group.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874095      PMCID: PMC372373          DOI: 10.1172/JCI108781

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Intestinal transport of phosphate: action of vitamin D, calcium, and potassium.

Authors:  H E HARRISON; H C HARRISON
Journal:  Am J Physiol       Date:  1961-12

2.  THE RENAL EXCRETION OF INORGANIC PHOSPHATE IN RELATION TO THE ACTION OF VITAMIN D AND PARATHYROID HORMONE.

Authors:  H E Harrison; H C Harrison
Journal:  J Clin Invest       Date:  1941-01       Impact factor: 14.808

3.  Study of intestinal absorption of calcium in patients with renal failure.

Authors:  J W Coburn; M H Koppel; A S Brickman; S G Massry
Journal:  Kidney Int       Date:  1973-04       Impact factor: 10.612

4.  The response of intestinal calcium transport to 25-hydroxy and 1,25-dihydroxy vitamin D in nephrectomized rats.

Authors:  I T Boyle; L Miravet; R W Gray; M F Holick; H F Deluca
Journal:  Endocrinology       Date:  1972-03       Impact factor: 4.736

5.  Competitive protein-binding radioassay for 25-hydroxycholecalciferol.

Authors:  J G Haddad; K J Chyu
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

Review 6.  Intestinal absorption of calcium and the effect of renal insufficiency.

Authors:  J W Coburn; D L Hartenbower; S G Massry
Journal:  Kidney Int       Date:  1973-08       Impact factor: 10.612

Review 7.  Caclium, phosphorus, and bone in renal disease and transplantation.

Authors:  N S Bricker; E Slatopolsky; E Reiss; L V Avioli
Journal:  Arch Intern Med       Date:  1969-05

8.  The metabolic fate of vitamin D3-3H in chronic renal failure.

Authors:  L V Avioli; S Birge; S W Lee; E Slatopolsky
Journal:  J Clin Invest       Date:  1968-10       Impact factor: 14.808

Review 9.  Third F. Raymond Keating, Jr., Memorial Symposium--parathyroid hormone, calcitonin and vitamin D: clinical considerations. II. Vitamin D--1973.

Authors:  H F DeLuca
Journal:  Am J Med       Date:  1974-07       Impact factor: 4.965

10.  Evidence for a direct action of cholecalciferol and 25-hydroxycholecalciferol on the renal transport of phosphate, sodium, and calcium.

Authors:  J B Puschett; J Moranz; W S Kurnick
Journal:  J Clin Invest       Date:  1972-02       Impact factor: 14.808

View more
  15 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 2.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

3.  Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.

Authors:  M S Sheikh; J A Maguire; M Emmett; C A Santa Ana; M J Nicar; L R Schiller; J S Fordtran
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

4.  Pathophysiology and treatment of uremic bone disease.

Authors:  J Coburn; J Kanis; M Popovtzer; E Ritz; E Slatopolsky; H Fleisch
Journal:  Calcif Tissue Int       Date:  1983-09       Impact factor: 4.333

5.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

Authors:  S Lopez-Hilker; T Galceran; Y L Chan; N Rapp; K J Martin; E Slatopolsky
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

6.  Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.

Authors:  E Slatopolsky; J Finch; M Denda; C Ritter; M Zhong; A Dusso; P N MacDonald; A J Brown
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

7.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

8.  Metabolic consequences of oral administration of 24,25-dihydroxycholecalciferol to uremic dogs.

Authors:  J M Canterbury; G Gavellas; J J Bourgoignie; E Reiss
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

9.  Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.

Authors:  R H Mak; C Turner; T Thompson; H Powell; G B Haycock; C Chantler
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-07

10.  Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure.

Authors:  C K Biswas; R S Arze; J M Ramos; M K Ward; J H Dewar; D N Kerr; D H Kenward
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.